Investigation of Sacroiliac Fusion Treatment (INSITE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare outcomes when patients with degenerative sacroiliitis (arthritis of the SI joint) and or sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint)undergo either SI joint fusion with the iFuse Implant System or undergo specific, targeted non-surgical treatment of the SI joint.
| Condition | Intervention | Phase |
|---|---|---|
|
Degenerative Sacroiliitis Sacroiliac Joint Disruption |
Device: iFuse Implant System Other: Non-surgical management |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | INSITE Investigation of Sacroiliac Fusion Treatment |
- Subject Success [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Composite endpoint of reduction from baseline in VAS back pain score by at least 20 mm, lack of device-related serious adverse events, absence of neurologic worsening and absence of surgical re-intervention.
- Improvement in Si joint pain [ Time Frame: Screening, 1, 3, 6, 12, 18 and 24 months ] [ Designated as safety issue: No ]Improvement in SI joint pain VAS score at post-operative visits
- Improvement in back dysfunction [ Time Frame: Screening, 1, 3, 6, 12 and 24 months ] [ Designated as safety issue: No ]Improvement in ODI at post-operative visits
- Improvement in quality of life [ Time Frame: Baseline, 6, 12 and 24 months ] [ Designated as safety issue: No ]Improvement in QOL as measured by SF-36 PCS and ED-5D at post-operative visits
- Ambulatory status [ Time Frame: Baseline, 1,3,6,12,18 and 24 months ] [ Designated as safety issue: No ]Time to full ambulation amongst those without full ambulation at baseline
- Work status [ Time Frame: Baseline, 1,3,6,12,18 and 24 months ] [ Designated as safety issue: No ]Proportion of non-working subjects who return to work
- Serious adverse events [ Time Frame: Procedure, discharge, 1, 3, 6, 12, 18 and 24 months ] [ Designated as safety issue: Yes ]Any event meeting ISO14155 definition for serious adverse event at following timepoints: during procedure (if randomized to iFuse), hospital discharge (if iFuse, typically 1-2 days), and 1, 3, 6, 12, 18 and 24 months after randomization.
| Estimated Enrollment: | 200 |
| Study Start Date: | September 2012 |
| Estimated Study Completion Date: | November 2014 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: iFuse Implant System
Surgical placement of iFuse implants in the affected SI joint
|
Device: iFuse Implant System
Placement of iFuse implant system via surgery
|
|
Active Comparator: Non-Surgical Management
Medications, SI joint injection, physical therapy and RF ablation of SI joint
|
Other: Non-surgical management
Medications for pain, physical therapy, SI joint injection and RF ablation
|
Eligibility| Ages Eligible for Study: | 21 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. Age 21-70 at time of screening
2. Patient has lower back pain for >6 months inadequately responsive to conservative care 3. Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:
- Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and
- Patient has at least 3 of 5 physical examination maneuvers specific for the SI joint (see Table 3), and
- Patient has improvement in lower back pain numeric rating scale (NRS) of at least 50% after injection of local anesthetic into affected SI joint(s) (see Section 3.6.4), and
One or more of the following:
SI joint disruption:
- Asymmetric SI joint widening on X-ray or CT scan, or
- Leakage of contrast on diagnostic arthrography
Degenerative sacroiliitis:
- Radiographic evidence of SI joint degeneration, including sclerosis, osteophytes, subchondral cysts, or vacuum phenomenon on CT or plain film, or
- Due to prior lumbosacral spine fusion
4. Baseline Oswestry Disability Index (ODI) score of at least 30%
5. Baseline SI joint pain score of at least 50 on 0-100 mm visual analog scale*
6. Patient has signed study-specific informed consent form
7. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
Exclusion Criteria:
- Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture**
Other known sacroiliac pathology such as:
- Sacral dysplasia
- Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy)
- Tumor
- Infection
- Acute fracture
- Crystal arthropathy
- History of recent (<1 year) major trauma to pelvis
- Previously diagnosed osteoporosis (defined as prior T-score <-2.5 or history of osteoporotic fracture). Patients meeting the osteoporosis screening criteria identified by the National Osteoporosis Foundation should be screened for osteoporosis with DEXA.**** See Section 3.6.4.
- Osteomalacia or other metabolic bone disease
- Chronic rheumatologic condition (e.g., rheumatoid arthritis)
- Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
- Chondropathy
- Known allergy to titanium or titanium alloys
- Use of medications known to have detrimental effects on bone quality and soft-tissue healing
- Prominent neurologic condition that would interfere with physical therapy
- Current local or systemic infection that raises the risk of surgery
- Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
- Currently pregnant or planning pregnancy in the next 2 years
- Patient is a prisoner or a ward of the state.
- Known or suspected drug or alcohol abuse***
- Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
- Patient is participating in an investigational study or has been involved in an investigational study within 3 months prior to evaluation for participation
Contacts and Locations| Contact: Kathryn Wine, MPH | 408-207-0700 ext 2215 | kwine@si-bone.com |
| Contact: Daniel C Cher, MD | 408-207-0700 ext 2233 | dcher@si-bone.com |
| United States, California | |
| University of California, San Diego | Recruiting |
| La Jolla, California, United States, 92093 | |
| Contact: Katie Lam 858-657-6125 kklam@ucsd.edu | |
| Principal Investigator: Farshad M Ahadian, MD | |
| Sub-Investigator: Yu-Po Lee, MD | |
| United States, Colorado | |
| University of Colorado Denver Health Sciences | Recruiting |
| Denver, Colorado, United States, 80045 | |
| Contact: Sarah Henry, MPH 720-848-1910 sarah.henry@ucdenver.edu | |
| Contact: Devin Razavi-Shearer, BA 720- 848-1910 devin.razavi-shearer@ucdenver.edu | |
| Principal Investigator: Vikas V Patel, MA, MD | |
| Sub-Investigator: Scott R Laker, MD | |
| Sub-Investigator: Evalina L Burger, MD | |
| Sub-Investigator: Christopher MJ Cain, MBBS, MD | |
| Sub-Investigator: Michael A Finn, MD | |
| Sub-Investigator: Susan Estes, NP | |
| Sub-Investigator: Robert Cooley, PA | |
| United States, Michigan | |
| St. Mary's of Michigan/Neurosciences Institute | Recruiting |
| Saginaw, Michigan, United States, 48604 | |
| Contact: Heather Clark 989-497-3023 hclark@stmarysofmichigan.org | |
| Principal Investigator: Kevin Lawson, MD | |
| United States, Minnesota | |
| University of Minnesota | Recruiting |
| Minneapolis, Minnesota, United States, 55455 | |
| Contact: Ivana Ninkovic 612-273-8082 nink0002@umn.edu | |
| Principal Investigator: Edward R Santos, MD | |
| Sub-Investigator: David W Polly, MD | |
| Sub-Investigator: Charles G Ledonio, MD | |
| United States, Missouri | |
| HCA Midwest | Recruiting |
| Kansas City, Missouri, United States, 64132 | |
| Contact: Amy Akins, RN 816-276-9652 amy.akins@hcamidwest.com | |
| Principal Investigator: William Rosenberg, MD | |
| United States, Oregon | |
| NeuroSpine Institute, LLC | Recruiting |
| Eugene, Oregon, United States, 97401 | |
| Contact: Shawn Potts 541-284-0530 spotts@neurospinellc.com | |
| Principal Investigator: Scott Kitchel, MD | |
| Sub-Investigator: Christopher Miller, MD | |
| Sub-Investigator: Gregory Moore, MD | |
| United States, South Carolina | |
| Medical University of South Carolina | Recruiting |
| Charleston, South Carolina, United States, 29425 | |
| Contact: Laura Fields 843-792-3131 fiela@musc.edu | |
| Principal Investigator: John Glaser, MD | |
| Sub-Investigator: Emily A Darr, MD | |
| United States, Texas | |
| Texas Back Institute | Recruiting |
| Plano, Texas, United States, 75093 | |
| Contact: Shannon Rusch, BA 972-608-5181 srusch@texasback.com | |
| Contact: Cheryl Murphy 972-608-5159 cmurphy@texasback.com | |
| Principal Investigator: Ralph F Rashbaum, MD | |
| Sub-Investigator: Michael S Hisey, MD | |
| Sub-Investigator: Nayan R Patel, MD | |
| United States, Washington | |
| Overlook Hospital Medical Center | Recruiting |
| Bellevue, Washington, United States, 98004 | |
| Contact: Tina M Fortney, RN, BSN 425-688-5407 Tina.Fortney@overlakehospital.org | |
| Contact: Marj Medina, RN 425-467-3986 Marjorie.Medina@overlakehospital.org | |
| Principal Investigator: Abhineet Chowdhary, MD | |
| Sub-Investigator: Hyun Hong, MD | |
| Sub-Investigator: Daniel E Nelson, MD | |
| United States, Wisconsin | |
| Midwest Orthopedic Specialty Hospital | Recruiting |
| Franklin, Wisconsin, United States, 53132 | |
| Contact: Tracy Mente, BSN 414-259-7327 Tracy.Mente@wfhc.org | |
| Principal Investigator: Clay J Frank, MD | |
More Information
No publications provided
| Responsible Party: | SI-BONE, Inc. |
| ClinicalTrials.gov Identifier: | NCT01681004 History of Changes |
| Other Study ID Numbers: | 300103 |
| Study First Received: | September 1, 2012 |
| Last Updated: | May 14, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by SI-BONE, Inc.:
|
si joint si joint pain si joint injury si joint treatment si joint injections si joint inflammation si joint problems si joint symptoms hypermobile si joint si joint arthritis |
si joint pain treatment inflamed si joint si joint sclerosis locked si joint si joint injuries si joint disease si joint infection sacroiliac joint pelvic pain sacroiliac joint arthritis treatment |
Additional relevant MeSH terms:
|
Sacroiliitis Arthritis Joint Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 23, 2013